Study on COVID-19 Infection, Immunity, and Vaccine Response in Malawi Tracking Transmission, Symptoms, and Long-term Antibody Changes

What this Trial Is About

Researchers are investigating why the impact of SARS-CoV-2 in sub-Saharan African countries, specifically Malawi, appears milder compared to Europe and the Americas. The study aims to understand how innate immune responses, malaria, intestinal parasites, undernutrition, and anemia influence infection risk, symptom progression, transmission, and responses to SARS-CoV-2 vaccination. They are assessing immune responses and vaccine effects in various groups to better understand susceptibility and immunity in this population. The study includes up to 200 symptomatic individuals confirmed with SARS-CoV-2 infection, their household contacts about 700, and up to 600 vaccine recipients aged 5 to 75 years. Participants undergo multiple visits for blood and stool sample collection over a follow-up period of up to 1.5 years. Vaccine recipients receive either the AstraZeneca or Johnson and Johnson vaccines, with samples collected at specific intervals after vaccination to monitor immune responses. Participants will have blood drawn at baseline and multiple follow-up visits to measure antibody levels, cellular immune responses, and markers of inflammation. Stool samples will be collected to diagnose intestinal parasites. Researchers will also monitor infection rates, symptom duration, and vaccine responses. The study will track these measures over time to assess how infections and vaccinations affect immunity and disease outcomes, with the overall participation lasting up to 15 months after initial enrollment.

COVID-19 Transmission and Morbidity in Malawi